Cancer Research

Mesothelioma has long remained one of the most difficult and aggressive cancers to treat within the modern medical landscape, primarily due to its ability to lie dormant for decades following asbestos exposure. By the time most patients receive a formal diagnosis, the disease has usually progressed

Recent breakthroughs in the field of molecular biology have unveiled a sophisticated biochemical mechanism that acts as a definitive binary toggle for malignant cellular proliferation, effectively governing the transition between dormant and aggressive tumor growth. For decades, oncologists

Ivan Kairatov is a leading figure in biopharmaceutical research, specializing in the intersection of molecular oncology and translational medicine. With a career dedicated to deciphering the metabolic vulnerabilities of treatment-resistant tumors, he has become a key voice in the development of

Clinicians have long faced the daunting challenge of synthesizing disparate fragments of patient information into a single, coherent diagnostic picture that accounts for both biology and lifestyle. As of now, the emergence of multimodal foundation models is finally bridging these gaps with

The oncological landscape has fundamentally shifted as researchers move away from the defeatist "undruggable" label that once defined the KRAS gene for nearly four decades of clinical frustration and failure. Today, the medical community is pivoting from merely managing terminal, late-stage

The medical landscape underwent a seismic shift recently when the Christie NHS Foundation Trust and the Royal Marsden launched the ZI-MA4-1 clinical trial, marking a pivotal moment for patients diagnosed with advanced solid tumors that have resisted standard treatments. For individuals like Tracy